[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"evaluation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:evaluation":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100581174","evaluation-of-the-quality-of-care-in-the-emergency-department-by-studying-the-appropriateness-of-hospitalizations-100581174",false,"NCT06846879","Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Hospitalizations","Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Hospitalizations: Validation of an Algorithm Based on Computerized Hospital Databases","Inclusion Criteria:\n\nAll patients aged 18 years and over who arrived at participating centres between 1 January 2023 and 31 December 2024.\n\nExclusion Criteria:\n\nAll patients under 18 years of age arriving at participating centers between January 1, 2023 and December 31, 2024 and all patients arriving at participating centers outside the time frame January 1, 2023 - December 31, 2024.","ALL","18 Years",{"count":19,"type":20},240000,"ESTIMATED","OBSERVATIONAL","The aim of this study is to develop, study and validate a rigorous and sustainable method for assessing the clinical appropriateness of the decision taken in the Emergency Department to admit or not to admit patients.",[24,25,26,27],"Quality of Care","Evaluation","Emergency Department","Appropriateness","RECRUITING","2026-05-18",{"date":31,"type":32},"2026-05-19","ACTUAL",{"date":34,"type":32},"2026-01-05",{"date":36,"type":20},"2027-06",{"name":38,"class":39},"Mario Negri Institute for Pharmacological Research","OTHER",7,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100414417","health-care-quality-in-semi-intensive-care-units-100414417","NCT04676347","Health-care Quality in Semi-intensive Care Units","Evaluation and Improvement of the Health-care Quality in Semi-intensive Care Units","Inclusion Criteria:\n\n* all patients hospitalised in a semi-intensive care unit\n\nExclusion Criteria:\n\n* None",{"count":49,"type":20},39000,"The main aim of this study is to realize a system of continuous evaluation of healthcare quality in semi-intensive care units.",[52,25,53],"Semi-intensive Care Unit","Quality",{"date":55,"type":32},"2026-05-20",{"date":57,"type":32},"2021-07-01",{"date":59,"type":20},"2029-12",{"name":38,"class":39},18,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100527000","recisttm-criteria-in-evaluating-the-efficacy-of-targeted-therapy-for-nsclc-100527000","NCT06142058","RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC","Application of the RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for Advanced Non-small Cell Lung Cancer With Positive Driving Genes","Inclusion Criteria:\n\n* NSCLC patients with stage IIIB-IV\n* Driver gene positive (EGFR,ALK,C-MET, ROS,RET, HER2);\n* First line targeted therapy.\n* Performance status of 0-2 on the ECOG criteria.\n* Any one of the tumor markers is more than three times higher than the normal level, and the tumor markers include: CEA\\>15ng\u002Fml,CA-199\\>105U\u002Fml,CA-125\\>105 U\u002Fml, NSE\\>60 ng\u002Fml, SCCAg\\>7.5 ng\u002Fml, CYFRA21-1\\>21 ng\u002Fml, et al.\n* Measurable lesions present\n* Age\\>=18\n* Adequate hematologic (neutrophil count \\>= 1,500\u002FuL, platelets \\>= 60,000\u002FuL,hemoglobin≥70g\u002FL), hepatic (transaminase =\\\u003C upper normal limit(UNL)x2.5, bilirubin level =\\\u003C UNLx1.5), and renal (creatinine =\\\u003C UNL) function.\n* Informed consent from patient or patient's relative.\n\nExclusion Criteria:\n\n* Patients with dysphagia;\n* Unable to taking medication on time;\n* Patients with a history of abuse of psychotropic substances who are unable to quit or have mental disorders",{"count":70,"type":20},44,"Investigators established the efficacy evaluation criteria for tumor markers (RecistTM) in the preliminary research. Among patients with advanced non-small cell lung cancer, patients with positive driving genes are more likely to exhibit abnormalities in tumor markers, which suggests that this criteria may be more suitable for evaluating the efficacy of targeted therapy in driving gene positive patients. Moreover, The judgment rules of the prelimary criteria still need further improvement. Therefore, in order to broaden the application scope of the RecistTM criteria, further improve the evaluation rules of RecistTM criteria, and multi-dimensionally confirm the reliability of RecistTM criteria on efficacy evaluation, investigators plan to conduct research on the application of RecistTM criteria in evaluating the efficacy of targeted therapy for advanced non-small cell lung cancer with positive driving genes.",[25,73,74],"NSCLC","Targeted Therapy",[76,73,77,78,79],"tumor marker","RECIST","RecistTM","positive driving gene","2023-11-15",{"date":82,"type":32},"2023-11-21",{"date":84,"type":20},"2023-11-13",{"date":86,"type":20},"2028-12-31",{"name":88,"class":39},"Xueqin Yang",1]